Christopher F Spurney

Summary

Affiliation: Children's National Medical Center
Country: USA

Publications

  1. pmc Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice
    Christopher F Spurney
    Children s National Heart Institute, Division of Cardiology, Children s National Medical Center, Washington, DC, USA
    BMC Cardiovasc Disord 11:20. 2011
  2. ncbi request reprint Fetal mouse imaging using echocardiography: a review of current technology
    Christopher F Spurney
    Division of Cardiology, Children s National Medical Center, Washington, DC 20010, USA
    Echocardiography 23:891-9. 2006
  3. pmc Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart
    Christopher F Spurney
    Center for Genetic Medicine Research, Children s National Medical Center, 111 Michigan Avenue, NW, Washington, DC 20010, USA
    Neuromuscul Disord 18:371-81. 2008
  4. doi request reprint Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions
    Christopher F Spurney
    Division of Cardiology, Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Muscle Nerve 44:8-19. 2011
  5. doi request reprint Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice
    Christopher F Spurney
    Division of Cardiology, Children s National Medical Center, Washington, DC, USA
    J Cardiovasc Pharmacol Ther 16:87-95. 2011
  6. doi request reprint Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures
    Christopher F Spurney
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Muscle Nerve 39:591-602. 2009
  7. pmc Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse
    Christopher F Spurney
    Division of Cardiology, Children s National Medical Center, Washington, District of Columbia, United States of America
    PLoS ONE 5:e8976. 2010
  8. pmc Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy
    Alfredo D Guerron
    Center for Genetic Medicine Research, Children s National Medical Center, Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    PLoS ONE 5:e11220. 2010
  9. pmc d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats
    Jay H Kramer
    Biochemistry and Molecular Biology, Division of Experimental Medicine, The George Washington University Medical Center, Washington, DC 20037, USA
    Can J Physiol Pharmacol 90:1257-68. 2012
  10. pmc The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice
    Arpana Sali
    Center for Genetic Medicine Research, Children s National Medical Center, Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    PLoS ONE 8:e66617. 2013

Collaborators

Detail Information

Publications20

  1. pmc Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice
    Christopher F Spurney
    Children s National Heart Institute, Division of Cardiology, Children s National Medical Center, Washington, DC, USA
    BMC Cardiovasc Disord 11:20. 2011
    ..The absence of dystrophin leads to loss of membrane integrity, cell death and fibrosis in cardiac muscle. Treatment of cardiomyocyte membrane instability could help prevent cardiomyopathy...
  2. ncbi request reprint Fetal mouse imaging using echocardiography: a review of current technology
    Christopher F Spurney
    Division of Cardiology, Children s National Medical Center, Washington, DC 20010, USA
    Echocardiography 23:891-9. 2006
    ....
  3. pmc Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart
    Christopher F Spurney
    Center for Genetic Medicine Research, Children s National Medical Center, 111 Michigan Avenue, NW, Washington, DC 20010, USA
    Neuromuscul Disord 18:371-81. 2008
    ..This is the first report of an altered profibrotic gene expression profile in cardiac tissue of dystrophic mice showing echocardiographic evidence of cardiomyopathy...
  4. doi request reprint Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions
    Christopher F Spurney
    Division of Cardiology, Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Muscle Nerve 44:8-19. 2011
    ..This review provides a summary of the current literature and discussion of potential new therapies for DMD cardiomyopathy...
  5. doi request reprint Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice
    Christopher F Spurney
    Division of Cardiology, Children s National Medical Center, Washington, DC, USA
    J Cardiovasc Pharmacol Ther 16:87-95. 2011
    ..Chronic treatment with losartan decreases cardiac and skeletal muscle fibrosis and improves cardiac systolic function in dystrophin-deficient mdx mice...
  6. doi request reprint Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures
    Christopher F Spurney
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Muscle Nerve 39:591-602. 2009
    ..These data provide an experimental basis upon which standardization of preclinical drug testing can be developed. Muscle Nerve, 2008...
  7. pmc Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse
    Christopher F Spurney
    Division of Cardiology, Children s National Medical Center, Washington, District of Columbia, United States of America
    PLoS ONE 5:e8976. 2010
    ....
  8. pmc Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy
    Alfredo D Guerron
    Center for Genetic Medicine Research, Children s National Medical Center, Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    PLoS ONE 5:e11220. 2010
    ..One of the proposed strategies is to use drugs that are known to act by multiple different mechanisms including inducing of homologous fetal form of adult genes, for example utrophin in place of dystrophin...
  9. pmc d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats
    Jay H Kramer
    Biochemistry and Molecular Biology, Division of Experimental Medicine, The George Washington University Medical Center, Washington, DC 20037, USA
    Can J Physiol Pharmacol 90:1257-68. 2012
    ..Since d-Pro is an antioxidant and reduces cardiac Fe uptake as well as inflammation, these properties may preserve cardiac function during Fe overload...
  10. pmc The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice
    Arpana Sali
    Center for Genetic Medicine Research, Children s National Medical Center, Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    PLoS ONE 8:e66617. 2013
    ..Although glucocorticoids remain the standard of care for the treatment of DMD, there is a need to investigate the efficacy of other pharmacological agents targeting the involvement of imbalances in ion flux on dystrophic pathology...
  11. pmc Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy
    Qing Yu
    Center for Genetic Medicine Research, Children s National Medical Center, Washington DC, United States of America
    PLoS ONE 8:e65468. 2013
    ..One form, MDC1A, is the result of laminin alpha-2 deficiency and results in significant weakness, respiratory insufficiency and early death. Modification of apoptosis is one potential pathway for therapy in these patients...
  12. doi request reprint Impact of pharmacotherapy on interstage mortality and weight gain in children with single ventricle
    Sunil J Ghelani
    Division of Cardiology, Children s National Medical Center, W111 Michigan Avenue NW, Washington, DC 20010, USA
    Congenit Heart Dis 8:219-27. 2013
    ..Despite widespread use, proton pump inhibitors and prokinetic agents are not associated with better outcomes and may be associated with poor growth...
  13. pmc Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse
    Arpana Sali
    Children s National Medical Center, Washington DC, United States of America
    PLoS ONE 7:e34204. 2012
    ..Our investigation addressed not only the effects of GC on the disease phenotype but also the question of whether GCs can be used as a positive control for preclinical drug evaluations...
  14. ncbi request reprint High-frequency ultrasound database profiling growth, development, and cardiovascular function in C57BL/6J mouse fetuses
    Christopher F Spurney
    Department of Cardiology, Children s National Medical Center, Washington, DC 20010, USA
    J Am Soc Echocardiogr 17:893-900. 2004
    ..However, lacking is a normative database of echocardiographic variables for monitoring growth and cardiovascular function...
  15. ncbi request reprint Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011
    Sunil J Ghelani
    Division of Cardiology, Division of Critical Care Medicine, and Clinical Data Operations, Children s National Medical Center, Washington, DC 20010, USA
    Circ Cardiovasc Qual Outcomes 5:622-7. 2012
    ..There is a lack of clear diagnostic and management guidelines for acute myocarditis in the pediatric population. We used a multi-institutional database to characterize demographics, practice variability, and outcomes in this population...
  16. ncbi request reprint Use of a hand-carried ultrasound device by critical care physicians for the diagnosis of pericardial effusions, decreased cardiac function, and left ventricular enlargement in pediatric patients
    Christopher F Spurney
    Department of Cardiology, Childrden s National Medical Center, Washington, DC 20010, USA
    J Am Soc Echocardiogr 18:313-9. 2005
    ..Left ventricular systolic function was correctly diagnosed in 22 of 23 patients (96%). These results show that, with appropriate instruction, pediatric critical care physicians are effective using limited portable echocardiography...
  17. pmc The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction
    William B Weglicki
    Department of Biochemistry and Molecular Biology, Division of Experimental Medicine, The George Washington University, Washington, DC 20037, USA
    Can J Physiol Pharmacol 90:1145-9. 2012
    ..Since hypomagnesemia alone can trigger oxidative stress and cardiac injury, we suggest that inhibition of EGFR-TK caused magnesium wasting, which partly contributed to decreased cardiac contractility...
  18. pmc CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy
    Christopher F Spurney
    Children s National Medical Center, George Washington University, Washington, DC, USA
    Muscle Nerve 44:174-8. 2011
    ..Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle...
  19. pmc Quercetin and ethanol attenuate the progression of atherosclerotic plaques with concomitant up regulation of paraoxonase1 (PON1) gene expression and PON1 activity in LDLR-/- mice
    Leslie C Leckey
    The Lipid Research Laboratory, Veterans Affairs Medical Center, Washington, District of Columbia 20422, USA
    Alcohol Clin Exp Res 34:1535-42. 2010
    ..Our objective is to demonstrate the potential benefits of the wine components, quercetin and ethanol, on the development of aortic plaques with parallel changes in antiatherogenic factors...
  20. pmc Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer
    Bo Wu
    McColl Lockwood Laboratory for Muscular Dystrophy, Neuromuscular ALS Center, Carolinas Medical Center, Charlotte, NC 28231, USA
    Proc Natl Acad Sci U S A 105:14814-9. 2008
    ..The high degree of potency of the oligomer in targeting all muscles and the lack of detectable toxicity and immune response support the feasibility of testing the novel oligomer in treating Duchenne muscular dystrophy patients...